Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3701_Библиотеки_им_академика_М_И_Перельмана
.pdf
Predicting Risk of Emerging Cardiotoxicity
DOI: http://dx.doi.org/10.5772/.105040
The Journal of Allergy and Clinical
371
https://t.me/medicina_free
Immunology in Practice (Cambridge,
MA). 2020;(1):188-194.e8.
DOI: 10.1016/j.jaip.2019.06.043
[29]
Murphy E, Steenbergen C.
Mechanisms underlying acute protection
from cardiac ischemia-reperfusion
injury. Physiological Reviews.
2008;(2):581-609. DOI: 10.1152/
physrev.00024.2007
[30]
Heusch G. Myocardial ischemiareperfusion injury and cardioprotection
in perspective. Nature Reviews in
Cardiology. 2020;:773-789
[31]
Yellon DM, Hausenloy DJ.
Myocardial reperfusion injury. The
New England Journal of Medicine.
2007;:1121-1135. DOI: 10.1056/
NEJMra071667
2020;:1764-1774. DOI: 10.1661/
CIRCULATIONAHA119.044408
[37] Kaya Z, Leib C, Katus H.
Autoantibodies in heart failure and
cardiac dysfunction. Circulation
Research. 2012;(1):145-158. DOI:
10.1161.CIRCRESAHA.111.243360
[38] Khamsi R. Rogue antibodies could
be driving severe COVID-19. Nature.
2021;:29-31
[39] Blagova O, Varionchik N,
Zaidenov V, Savina P, Sarkisova N.
Anti-heart antibodies levels and their
correlation with clinical symptoms and
outcomes in patients with confirmed
or suspected diagnosis COVID-19.
European Journal of Immunology.
2021;:893-902. DOI: 10.1002/
eji.202048930
[32]
Hausenloy DJ, Candilio L, Evans R,
Cono A, Jenkins DP, Kolvekar S, et al.
The New England Journal of Medicine.
2015;:1408-1417. DOI: 10.1056/
NEJMoa1413534
[33]
Brook RD, Franklin B, Cascio W,
Hong Y, Howard G, Lipsett M, et al. Air
Polution and cardiovascular disease.
Circulation. 2004;(21):2655-2271
[34]
Franklin BA, Brook R, Pope CA
III. Air pollution and cardiovascular
disease. Current Problems in Cardiology.
2015;:207-238
[35]
Al-Kindi SG, Brook RD,
Bisawal S, Rajagopalan S. Environmental
determinants of cardiovascular
disease: Lessons learned from air
pollution. Nature Reviews Cardiology.
2020;(17):656-672
[36]
Maguy A, Tardif J-C, Busseuil D,
Ribi C, Li J. Autoantibody signature
in cardiac arrest. Circulation.
[40] Carll AP, Willis MS, Lust RM,
Costa DL, Farraj AK. Merits of noninvasive rat models of left ventricular
heart failure. Cardiovascular Toxicology.
2011;(2):91-112. DOI: 10.1007/s12012-
011-9103-5 PMID: 21279739
[41] Corremans R, Adão R, De
Keulenaer GW, Leite-Moreira AF,
Brás-Silva C. Update on pathophysiology
and preventive strategies of
anthracycline-induced cardiotoxicity.
Clinical and Experimental Pharmacology
& Physiology. 2019;(3):204-215.
DOI: 10.1111/1440-1681.13036
PMID: 30244497
[42] Timm KN, Tyler DJ. The role of
AMPK activation for Cardioprotection
in doxorubicin-induced cardiotoxicity.
Cardiovascular Drugs and Therapy
2020;(2):255-269. DOI: 10.1007/
s10557-020-06941-x. PMID: 32034646;
PMCID: PMC7125062. 8
[43] Kang YJ. Molecular and cellular
mechanisms of cardiotoxicity.

Novel Pathogenesis and Treatments for Cardiovascular Disease
372
https://t.me/medicina_free
Environmental Health Perspectives.
2001;(Suppl. 1):27-34. DOI: 10.1289/
ehp.01109s127
[44] Fabiani I, Aimo A, Grigoratos C,
etal. Oxidative stress and inflammation:
Determinants of anthracycline
cardiotoxicity and possible therapeutic
targets. Heart Failure Reviews.
2021;:881-890. DOI: 10.1007/
s10741-020-10063-9
[45] Zhang S, Liu X, Bawa-Khalfe T, etal.
Identification of the molecular basis of
doxorubicin-induced cardiotoxicity.
Nature Medicine. 2012;:1639-1642.
DOI: 10.1038/nm.2919
[46] Zhu H, Sarkar S, Scott L, Danelisen I,
Trush MA, Jia Z, et al. Doxorubicin redox
biology: Redox cycling, topoisomerase
inhibition, and oxidative stress.
Reactive Oxygen Species (Apex, N.C.).
2016;(3):189-198. DOI: 10.20455/
ros.2016.83513
[47] Rabinovich-Nikitin I,
Love M, Kirshenbaum LA. Inhibition
of MMP prevents doxorubicin-induced
cardiotoxicity by attenuating cardiac
intracellular and extracellular matrix
remodelling. Cardiovascular Research.
2021;(1):11-12. DOI: 10.1093/cvr/
cvaa198
[48] Aries A, Paradis P, Lefebvre C,
Schwartz RJ, Nemer M. Essential role
of GATA-4 in cell survival and druginduced cardiotoxicity. Proceedings
of the National Academy of Sciences
of the United States of America.
2004;(18):6975-6980. DOI: 10.1073/
pnas.0401833101
[49] Park AM, Nagase H, Liu L, Vinod
Kumar S, Szwergold N, Wong CM, et al.
Mechanism of anthracycline-mediated
down-regulation of GATA4 in the heart.
Cardiovascular Research. 2011;(1):97-
104. DOI: 10.1093/cvr/cvq36110
[50] Dudek J, Hartmann M, Rehling P.
The role of mitochondrial cardiolipin
in heart function and its implication in
cardiac disease. Biochimica et Biophysica
Acta (BBA) - Molecular Basis of Disease.
2019;(4):810-821. DOI: 10.1016/j.
bbadis.2018.08.025
[51] Zhao L, Zhang B. Doxorubicin
induces cardiotoxicity through
upregulation of death receptors mediated
apoptosis in cardiomyocytes. Scientific
Reports. 2017;:44735. DOI: 10.1038/
srep44735
[52] Nakamura T, Ueda Y, Juan Y,
Katsuda S, Takahashi H, Koh E. Fasmediated apoptosis in adriamycininduced cardiomyopathy in rats: In vivo
study. Circulation. 2000;(5):572-578.
DOI: 10.1161/01.cir.102.5.572
[53] Guo R, Xu W, Lin J, Mo L,
Hua X, Chen P, et al. Activation of the
p38 MAPK/NF-κB pathway contributes
to doxorubicin-induced inflammation
and cytotoxicity in H9c2 cardiac cells.
Molecular Medicine Reports. 2013;:603-
608. DOI: 10.3892/mmr.2013.1554
[54] Putt M, Hahn VS, Januzzi JL,
Sawaya H, Sebag IA, Plana JC, et al.
Longitudinal changes in multiple
biomarkers are associated with
cardiotoxicity in breast Cancer patients
treated with doxorubicin, Taxanes,
and Trastuzumab. Clinical Chemistry.
2015;(9):1164-1172. DOI: 10.1373/
clinchem.2015.241232
[55] Beer LA,Kossenkov AV, Liu Q ,
Luning Prak E, Domchek S,
Speicher DW, et al. Baseline
immunoglobulin E levels as a
marker of doxorubicin- and
Trastuzumab-associated cardiac
dysfunction. Circulation Research.
2016;(10):1135-1144. DOI: 10.1161/
CIRCRESAHA.116.309004

Predicting Risk of Emerging Cardiotoxicity
DOI: http://dx.doi.org/10.5772/.105040
[56]
373
https://t.me/medicina_free
Koutsoukis A, Ntalianis A,
Repasos E, Kastritis E, Dimopoulos MA,
Paraskevaidis I. Cardio-oncology:
A focus on cardiotoxicity. European
Cardiology. 2018;(1):64-69.
DOI: 10.15420/ecr.2017:17:2
[57]
Varga ZV, Ferdinandy P, Liaudet L,
Pacher P. Drug-induced mitochondrial
dysfunction and cardiotoxicity.
American Journal of Physiology.
Heart and Circulatory Physiology.
2015;(9):H1453-H1467. DOI: 10.1152/
ajpheart.00554.2015
[58]
Grazette LP, Boecker W, Matsui T,
Semigran M, Force TL, Hajjar RJ, et al.
Inhibition of ErbB2 causes mitochondrial
dysfunction in cardiomyocytes:
Implications for herceptin-induced
cardiomyopathy. Journal of the
American College of Cardiology.
2004;(11):2231-2238. DOI: 10.1016/j.
jacc.2004.08.066
[59]
Crone SA, Zhao YY, Fan L, Gu Y,
Minamisawa S, Liu Y, et al. ErbB2 is
essential in the prevention of dilated
cardiomyopathy. Nature Medicine.
2002;(5):459-465. DOI: 10.1038/
nm0502-459
[60]
Vasti C, Hertig CM. Neuregulin-1/
erbB activities with focus on
the susceptibility of the heart to
anthracyclines. World Journal of
Cardiology. 2014;(7):653-662.
DOI: 10.4330/wjc.v6.i7.653
[61]
Iqubal A, Iqubal MK,
Sharma S, Ansari MA, Najmi AK,
Ali SM, et al. Molecular mechanism
involved in cyclophosphamide-induced
cardiotoxicity: Old drug with a new
vision. Life Sciences. 2019;:112-131.
DOI: 10.1016/j.lfs.2018.12.018
[62]
Omole JG, Ayoka OA, Alabi QK,
Adefisayo MA, Asafa MA, Olubunmi BO,
et al. Protective effect of Kolaviron
on cyclophosphamide-induced
cardiac toxicity in rats. Journal of
Evidence-Based Integrative Medicine.
2018;:2156587218757649.
DOI: 10.1177/2156587218757649
[63] Al-Nasser IA. In vivo prevention
of cyclophosphamide-induced Ca2+
dependent damage of rat heart and
liver mitochondria by cyclosporin
a. Comparative Biochemistry and
Physiology Part A: Molecular &
Integrative Physiology. 1998;(3):
209-214. DOI: 10.1016/s1095-6433(98)
10135-6
[64] Asiri YA. Probucol attenuates
cyclophosphamide-induced oxidative
apoptosis, p53 and Bax signal expression
in rat cardiac tissues. Oxidative Medicine
and Cellular Longevity. 2010;(5):308-
316. DOI: 10.4161/oxim.3.5.13107
[65] Avci H, Epikmen ET, Ipek E,
Tunca R, Birincioglu SS, Akşit H, etal.
Protective effects of silymarin and
curcumin on cyclophosphamide-induced
cardiotoxicity. Experimental and
Toxicologic Pathology: Official Journal
of the Gesellschaft fur Toxikologische
Pathologie. 2017;(5):317-327.
DOI: 10.1016/j.etp.2017.02.002
[66] Refaie MMM, Shehata S,
El-Hussieny M, et al. Role of ATPsensitive Potassium Channel (KATP) and
eNOS in mediating the protective effect
of Nicorandil in cyclophosphamideinduced cardiotoxicity. Cardiovascular
Toxicology. 2020;:71-81. DOI: 10.1007/
s12012-019-09535-8
[67] Lushnikova EL, Nepomnyashchikh
LM, Sviridov EA, et al. Ultrastructural
signs of cyclophosphamide-induced
damage to cardiomyocytes. Bulletin of
Experimental Biology and Medicine.
2008; :366-371. DOI: 10.1007/
s10517-008-0287-z

Novel Pathogenesis and Treatments for Cardiovascular Disease
374
https://t.me/medicina_free
[68] Carlson LE, Watt GP,
Tonorezos ES, Chow EJ, Yu AF,
Woods M, et al. Coronary artery disease
in young women after radiation therapy
for breast Cancer: The WECARE study.
JACC: CardioOncology. 2021;(3):381-
392. DOI: 10.1016/j.jaccao.2021.07.008
PMID: 34604798; PMCID: PMC8463731
[69] Correa CR, Litt HI, Hwang WT,
Ferrari VA, Solin LJ, Harris EE. Coronary
artery findings after left-sided compared
with right-sided radiation treatment
for early-stage breast cancer. Journal of
Clinical Oncology. 2007;(21):3031-
3037. DOI: 10.1200/JCO.2006.08.6595
PMID: 17634481
[70] Sardar P, Kundu A, Chatterjee S,
Nohria A, Nairooz R, Bangalore S, et
al. Long-term cardiovascular mortality
after radiotherapy for breast cancer: A
systematic review and meta-analysis.
Clinical Cardiology. 2017;(2):73-81.
DOI: 10.1002/clc.22631 PMID: 28244595;
PMCID: PMC6490535
[71] Jimenez RB, Wong SM, Johnson A,
Lalani N, Hughes KS. The association
between cardiac mortality and adjuvant
radiation therapy among older patients
with stage I Estrogen positive breast
Cancer: A surveillance, epidemiology,
and end results (SEER)-based study on
cardiac mortality and radiation therapy.
Advances in Radiation Oncology.
2020;(2):100633. DOI: 10.1016/j.
adro.2020.100633 PMID: 33912735;
PMCID: PMC8071719
[72] Gardner DG, Chen S, Glenn DJ.
Vitamin D and the heart. American
Journal of Physiology. Regulatory,
Integrative and Comparative Physiology.
2013;(9):R969-R977. DOI: 10.1152/
ajpregu.00322.2013
[73] Polat V, Bozcali E, Uygun T,
Opan S, Karakaya O. Low vitamin
D status associated with dilated
cardiomyopathy. International Journal
of Clinical and Experimental Medicine.
2015;(1):1356-1362
[74]
Chiodini I, Gatti D, Soranna D,
Merlotti D, Mingiano C, Fassio A, etal.
Vitamin D status and SARS-CoV-2
infection and COVID-19 clinical
outcomes. Frontiers in Public Health.
2021;:736665. DOI: 10.3389/
fpubh.2021.736665 PMID: 35004568;
PMCID: PMC8727532
[75]
Sciatti E, mbardi C, Ravera A,
Vizzardi E, Bonadei I, Carubelli V, et al.
Nutritional deficiency in patients with
heart failure. Nutrients. 2016;(7):442.
DOI: 10.3390/nu8070442
[76]
Qu H, Guo M, Chai H, Wang WT,
Gao ZY, Shi DZ. Effects of coenzyme Q10
on statin-induced myopathy: An updated
Meta-analysis of randomized controlled
trials. Journal of the American Heart
Association. 2018;(19):e009835.
DOI: 10.1161/JAHA.118.009835.
PMID: 30371340; PMCID: PMC6404871
[77]
Langsjoen PH, Langsjoen JO,
Langsjoen AM, Rosenfeldt F. Statinassociated cardiomyopathy responds to
statin withdrawal and administration
of coenzyme Q10. The Permanente
Journal. 2019;:18-257. DOI: 10.7812/
TPP/18.257 PMID: 31496499;
PMCID: PMC6730959
[78]
Jiang J-B, Balschi JA Jr, F. X.,
& He, H. Thiazolidinediones cause
cardiotoxicity via PPARγ- independent
mechanism. Cardiotoxicity. 2018.
DOI: 10.5772/.78957
[79]
Sambandam N, Morabito D,
Wagg C, Finck BN, Kelly DP,
Lopaschuk GD. Chronic activation of
PPARα is detrimental to cardiac recovery
after ischemia. American Journal of
Physiology. Heart and Circulatory
Physiology. 2006;:H87-H95

Predicting Risk of Emerging Cardiotoxicity
DOI: http://dx.doi.org/10.5772/.105040
[80]
375
https://t.me/medicina_free
Baik A, Oluwole O, Johnson D,
Shah N, Salem J-E, et al. Cardiovascular
toxicities and immunotherapies.
Circulation Research. 2021;
(11):1780-1801. DOI: 10.1161/
CIRCRESAHA.120.315894
[81]
Woodward TE, FR MC Jr, Carey TN,
Togo Y. Viral and rickettsial causes
of cardiac disease, including the
Coxsackie virus etiology of pericarditis
and myocarditis. Annals of Internal
Medicine. 1960;:1130-1150.
DOI: 10.7326/0003-4819-53-6-1130
PMID: 13786607
[82]
Kim KS, Hufnagel G, Chapman NM,
Tracy S. The group B coxsackieviruses
and myocarditis. Reviews in Medical
Virology. 2001;(6):355-368.
DOI: 10.1002/rmv.326 PMID: 11746998
[83]
Tam PE. Coxsackie virus myocarditis:
Interplay between virus and host in
the pathogenesis of heart disease. Viral
Immunology. 2006;(2):133-146.
DOI:10.1089/vim.2006.19.133
PMID:16817756
[84]
Fairweather D, Rose NR.
Coxsackievirus-induced myocarditis in
mice: A model of autoimmune disease
for studying immunotoxicity. Methods.
2007;(1):118-122. DOI: 10.1016/j.
ymeth.2006.07.009. PMID: 17161308;
PMCID: PMC1764911
[85]
Freiberg MS, So-Armah K. HIV
and cardiovascular disease: We need a
mechanism, and we need a plan. Journal
of the American Heart Association.
2016;(3):e003411. DOI: 10.1161/
JAHA.116.003411. PMID: 27013540;
PMCID: PMC4943288
[86]
Freiberg MS, Chang CC, Kuller LH,
Skanderson M, Lowy E, Kraemer KL,
etal. HIV infection and the risk of acute
myocardial infarction. JAMA Internal
Medicine. 2013;:614-622
[87] Butt AA, Chang CC,
Kuller L, Goetz MB, Leaf D, Rimland D,
et al. Risk of heart failure with human
immunodeficiency virus in the absence
of prior diagnosis of coronary heart
disease. Archives of Internal Medicine.
2011;:737-743
[88] Ni W, Yang X, Yang W, Bao J, Xiao Y,
et al. Role of angiotensin-converting
enzyme 2 (ACE2) in COVID-19. Critical
Care. 2020;:422. DOI: doi.org/10.1186/
s13054-020-03120-0
[89] Libby P, Lüscher T. COVID-19 is, in
the end, an endothelial disease. European
Heart Journal. 2020;(32):3038-3044.
DOI: 10.1093/eurheartj/ehaa623
PMID: 32882706; PMCID: PMC7470753
[90] Evans PC, Rainger GE, Mason JC,
Guzik TJ, Osto E, Stamataki Z, et al.
Endothelial dysfunction in COVID-19:
A position paper of the ESC working
Group for Atherosclerosis and Vascular
Biology, and the ESC Council of basic
cardiovascular science. Cardiovascular
Research. 2020;(14):2177-2184.
DOI: 10.1093/cvr/cvaa230
PMID: 32750108; PMCID: PMC7454368
[91] Puntmann V, Carej M, Wieters I,
Fahim M, Arendt C, et al. Outcomes
of cardiovascular magnetic resonance
imaging in patients recently recovered
from coronavirus disease 2019 (COVID-
19). JAMA Cardiology. .
DOI: 10.1001/jamacardio.2020.3557
[92] Nishiga M, Wang DW,
Han Y, Lewis DB, Wu JC. COVID-19
and cardiovascular disease: From basic
mechanisms to clinical perspectives.
Nature Reviews. Cardiology
2020;(9):543-558. DOI: 10.1038/
s41569-020-0413-9. PMID: 32690910;
PMCID:PMC7370876.
[93] Guzik TJ, Mohiddin SA, Dimarco A,
Patel V, Savvatis K, Marelli-Berg FM,

Novel Pathogenesis and Treatments for Cardiovascular Disease
376
https://t.me/medicina_free
et al. COVID-19 and the cardiovascular
system: Implications for risk
assessment, diagnosis, and treatment
options. Cardiovascular Research.
2020;(10):1666-1687. DOI: 10.1093/
cvr/cvaa106 PMID: 32352535;
PMCID: PMC7197627
[94] Ratchford SM, Stickford JL,
Province VM, Stute N, Augenreich MA,
Koontz LK, et al. Vascular alterations
among young adults with SARS-CoV-2.
American Journal of Physiology.
Heart and Circulatory Physiology.
2021;(1):H404-H410. DOI: 10.1152/
ajpheart.00897.2020 PMID: 33306450;
PMCID: PMC8083172
[95] Hazarika S, Van Scott MR,
Lust RM. Airborne allergen increases
severity of myocardial injury following
ischemia-reperfusion in allergic mice.
American Journal of Physiology.
Heart and Circulatory Physiology.
2007;(1):H572-H579.
PMID: 16905595
[96] Hazarika S, Van Scott MR, Lust RM,
Wingard CJ. Pulmonary allergic reactions
impair systemic vascular relaxation
in ragweed sensitive mice. Vascular
Pharmacology. 2010;(5-6):258-263
PMID: 20888432
[97] Wingard CJ, Cozzi E, van Scott MR,
Lust RM. Particulate exposures and
cardiovascular inflammation. Chapter 5.
In: Meggs W, editor. Toxicant Induction
of Irritant Asthma, Rhinitis, and Related
Conditions. New York: Springer; 2013.
ISBN 978-1-4614-9043-2
[98] Brook RD. Why physicians
whotreat hypertension should
know more about air pollution. The
Journal ofClinical Hypertension.
2007;(8):629-635. DOI: 10.1111/
j.1524-6175.2007.07187.x
[99] Lee BJ, Kim B, Lee K. Air pollution
exposure and cardiovascular disease.
Toxicology Research. 2014;(2):71-75.
DOI: 10.5487/TR.2014.30.2.071
[100] Simkhovich BZ, Kleinman MT,
Kloner RA. Air pollution and
cardiovascular injury. Journal of the
American College of Cardiology.
2008;(9):719-726. DOI: 10.1016/j.
jacc.2008.05.029
[101] Bourdrel T, Bind MA, Béjot Y,
Morel O, Argacha JF. Cardiovascular
effects of air pollution. Archives
of Cardiovascular Diseases.
2017;(11):634-642. DOI: 10.1016/j.
acvd.2017.05.003
[102] Bostan HB, Rezaee R, Valokala MG,
et al. Cardiotoxicity of nano-particles.
Life Sciences. 2016;:91-99.
DOI: 10.1016/j.lfs.2016.09.017
[103] Gold DR, Litonjua A,
Schwartz J, et al. Ambient pollution
and heart rate variability. Circulation.
2000;(11):1267-1273. DOI: 10.1161/
01.cir.101.11.1267
[104] Cozzi E, Hazarika S, Stallings HW,
Cascio WE, Devlin RB, Lust RM, et al.
Ultrafine particulate matter exposure
augments ischemia reperfusion injury in
mice. American Journal of Physiology.
Heart and Circulatory Physiology.
2006;(2):H894-H903. PMID: 16582015
[105] Cascio WE, Cozzi E, Devlin RB,
Henriksen RA, Lust RM, Van Scott MR,
et al. Cardiac and vascular changes
in mice after exposure to ultrafine
particulate matter. Inhalation Toxicology.
2007;(Suppl. 1):67-73 PMID: 17886053
[106] Cozzi E, Wingard CJ, Cascio WE,
Devlin RB, Miles JJ, Bofferding AR, etal.
Effect of ambient particulate matter
exposure on hemostasis. Translational
Research. 2007;(6):324-332.
PMID: 17543851

Predicting Risk of Emerging Cardiotoxicity
DOI: http://dx.doi.org/10.5772/.105040
[107]
377
https://t.me/medicina_free
Carll AP, Lust RM, Hazari MS,
Perez CM, Krantz QT, King CJ, et al.
Diesel exhaust inhalation increases
cardiac output, bradyarrhythmias,
and parasympathetic tone in aged
heart failure-prone rats. Toxicological
Sciences. 2013, 2013;(2):583-595.
PMID:23047911
[108]
Kan H, Pan D, Castranova V.
Engineered nanoparticle exposure and
cardiovascular effects: The role of a
neuronal-regulated pathway. Inhalation
Toxicology. 2018;(9-10):335-342.
DOI: 10.1080/08958378.2018.1535634
[109]
Wingard CJ, Walters DM,
Cathey BL, Hilderbrand SC,
Katwa P, Lin S, et al. Mast cells contribute
to altered vascular reactivity and
ischemia-reperfusion injury following
cerium oxide nanoparticle instillation.
Nanotoxicology. 2011;(4):531-545.
PMID: 20888432
[110]
Thompson LC, Urankar RN,
Holland NA, Vidanapathirana AK,
Pitzer JE, Han L, et al. C60 exposure
augments cardiac ischemia/reperfusion
injury and coronary artery contraction
in Sprague-Dawley rats. Toxicological
Sciences. 2014;(2):365-378.
DOI:10.1093/toxsci/kfu008
PMID:24431213
[111]
Holland NA, Becak DP,
Shannahan JH, Brown JM, Carratt SA,
Van Winkle LS, et al. Cardiac ischemia
reperfusion injury following instillation of
20 nm citrate-capped Nanosilver. Journal
of Nanomedicine & Nanotechnology.
2015;S. DOI: 10.4172/2157-7439.S6-006
PMID:26966636
[112]
Holland NA, Thompson LC,
Vidanapathirana AK, Urankar RN,
Lust RM, Fennell TR, et al. Impact
of pulmonary exposure to gold core
silver nanoparticles of different size
and capping agents on cardiovascular
injury. Particle and Fibre Toxicology.
2016;(1):48-69. DOI: 10.1186/s12989016-0159-z PMID:27558113
[113] Urankar RM, Lust RM,
Mann E, Katwa P, Wang X, Podila R,
et al. Expansion of cardiac ischemia/
reperfusion injury after instillation of
three forms of multi-walled carbon
nanotubes. Particle and Fibre Toxicology.
2012;(9):38 PMID:23072542
[114] Gottumukkala RV, Lv H,
Cornivelli L, Wagers AJ, Kwong RY,
Bronson R, et al. Myocardial infarction
triggers chronic cardiac autoimmunity
in type 1 diabetes. Science Translational
Medicine. 2012;(138):138ra80.
DOI:10.1126/scitranslmed.3003551
PMID: 22700956; PMCID: PMC4303259
[115] Frustaci A, Cuoco L, Chimenti C,
Pieroni M, Fioravanti G, Gentiloni N,
et al. Celiac disease associated with
autoimmune myocarditis. Circulation.
2002;(22):2611-2618. DOI:10.1161/01.
cir.0000017880.86166.87.
PMID:12045166
[116] Al-Hussaini A, Sulaiman N,
Al-Zahrani M, Alenizi A, El Haj I. High
prevalence of celiac disease among
Saudi children with type 1 diabetes:
A prospective cross-sectional study.
BMC Gastroenterology. 2012;:180.
DOI:10.1186/1471-230X-12-180.
PMID:23259699; PMCID: PMC3543703
[117] Sousa GR, Niewczas M. Lipes MA;
251-OR: Cardiac autoantibodies (AB)
predict cardiovascular disease (CVD)
in T1D and are associated with cytokine
signatures linked to CVD risk. Diabetes.
2020;(Supplement_1) 251–OR.
DOI:10.2337/db20-251-OR
[118] Caforio A, Mahon N,
Tona F, McKenna W. Circulating cardiac
autoantibodies in dilated cardiomyopathy
and myocarditis: Pathogenetic and

Novel Pathogenesis and Treatments for Cardiovascular Disease
378
https://t.me/medicina_free
clinical significance. European Journal of
Heart Failure. 2002;-
[119] Caforo A, Tona F, Bottaro S, Vinvi A,
Dequal G, et al. Clinical implications
of anti-heart autoantibodies in
myocarditis and dilated cardiomyopathy.
Autoimmunity. 2008;:35-45.
DOI:10.1080.08916930701619235
[120] Moraru M, Roth A, Keren G,
George J. Cellular autoimmunity to
cardiac myosin in patients with a recent
myocardial infarction. International
Journal of Cardiology. 2006;:61-66.
DOI: 10.1016/j.ijcard.2005.02.036
[121] Calabrese F, Thiene G. Myocarditis
and inflammatory cardiomyopathy:
Microbiological and molecular
biological aspects. Cardiovascular
Research. 2003;:11-25. DOI: 10.1016/
S008-6363(03)00475-9
[122] Mandal K, Jahangiri J, Mukhin M,
Poloniecki J, Camm A, et al. Association
of anti-heat shock protein 65 antibodies
with development of postoperative
atrial fibrillation. Circulation.
2004:2588-2590. DOI: 10.1161/01.
CIR.0000136825.96029.A5
[123] Kossowsky W, Epstein J, Levine R.
Post myocardial infarction syndrome:
An early complication acute myocardial
infarction. Chest. 1973;:35-40.
DOI: 10.1378/chest.63.1.35
to acute rejection of cardiac allografts
in miniature swine. Transplantation.
2011;:1187-1191. DOI: 10.1097/
TP.0b013e318218415d
[126] Mascaro-Blanco A, Alvarez K,
Yu X, Lindenfeld J, Olansky L, et al.
Consequences of unlocking the cardiac
myosin molecule in human
myocarditis and cardiomyopathies.
Autoimmunity. 2008;:442-453.
DOI:10.1080/08916930802031579
[127] Bracamonte-Baran W, Cihakova D.
Cardiac autoimmunity; myocarditis.
Advances in Experimental Medicine
and Biology. 2017;:187-221.
DOI:10.1007/978-3-319-57613-8_10
[128] Mocumbi A, Latif N, Yacoub M.
Presence of circulating anti-myosin
antibodies in endomyocardial fibrosis.
PLoS Neglected Tropical Diseases.
2010;(4)
[129] Ono M, Shimizu J, Miyachi Y,
Sakaguchi S. Control of autoimmune
myocarditis and multiorgan
inflammation by glucocorticoidinduced TNF receptor family-related
protein foxp3-expressing-CD25 and
CD25 regulatory T cells. Journal of
Immunology. 2006;:4748-4756.
DOI:10.4049/jimmunol.176.4748
[124] Deubner N, Berliner D, Schlipp A,
Gelbrich G, Caforio A, et al. Cardiac
B1-adrenoceptor autoantibodies in
human heart disease: Rationale and
design of the etiology, time-course, and
survival (ETiCS) study. European Journal
of Heart Failure. 2010;:753-7662.
DOI:10.1093/eurjhf/hfq072
[125] Sahara H, Meltzer A, Weiss M,
Iwamoto Y, et al. Autoimmune
sensitization to cardiac myosin leads

Chapter 18
379
https://t.me/medicina_free
Echocardiographic Prognostic
Factors in Pulmonary Hypertension
Gabriela Silvia Gheorghe, Andrei Cristian Dan Gheorghe,
Ana Ciobanu and Andreea Simona Hodorogea
Abstract
Pulm
onary h
pressure of ≥25 mmHg at rest by right heart catheterization. Echocardiography estimates
systolic pulmonary arterial pressure on the tricuspid regurgitation jet velocity, mean and
diastolic pressure based on the pulmonary regurgitation jet, and data regarding the
function of the right ventricle. ESC guidelines propose an echocardiographic risk assessment in PH according to right atrial area > 26 cm
factors correlated with the severity of the PH include right atrial pressure > 15 mmHg,
tricuspid regurgitation more than moderate, TAPSE <18 mm, tricuspid S0 < 11.5 cm/s
assessed by TDI, right ventricle ejection fraction < 45% using 3D imaging, fractional area
change of the right ventricle < 35%, dP/dt < 400 mmHg/s on the tricuspid regurgitation
flow, reduced strain of the right ventricle, diastolic dysfunction. Left ventricular eccentricity index (EI) >1.7 combined with TAPSE <15 mm was associated with a higher
death rate compared to patients with normal values. However, each of these parameters
used in the assessment of the right ventricle has technical limitations, and it is necessary
to use multiple tests for a correct evaluation of the prognosis of PH.
Keywords: pulmonary hypertension, tricuspid regurgitation, right ventricle,
right atrium, global strain
ypertension (PH) is defined as an increase in mean pulmonary arterial
2
and pericardial effusion. Other risk
1. Introduction
Pulmonary hypertension (PH) is defined as an increase in mean pulmonary arterial
pressure (mPAP) of ≥25 mmHg at rest as assessed by right heart catheterization.
Current data have shown that the normal mPAP at rest is 14 3 mmHg with the
upper limit of normal of approximately 20 mmHg. The clinical significance of mPAP
between 21 and 24 mmHg is unclear [1]. There are also unclear data regarding the
normal versus exaggerated elevation of mPAP at physical effort, making it difficult to
put the diagnosis of exercise-induced PH. Pulmonary vascular resistance (PVR) with a
cut-off of ≥3 Wood units has been included in the hemodynamic diagnosis of PH, and
pulmonary artery wedge pressure (PAWP) with a cut-off of ≥15 mmHg is used for the
classification of PH in pre-capillary, post-capillary, or combined pre- and postcapillary PH [1]. PH is classified into five groups, depending on the underlying
disease [1].

Novel Pathogenesis and Treatments for Cardiovascular Disease
380
https://t.me/medicina_free
Not all patients with PH perform right heart catheterization, and, in practice, the
diagnosis of PH is based on the echocardiographic evaluation of the pulmonary artery
pressure. Also, echocardiography can detect the underlying disease and the consequences of the PH on the right and left ventricles (Table 1), [2–8]. Nevertheless, the
echocardiographic evaluation of the right heart is more difficult than that of the left
heart because of the complex shape of the right ventricle (RV) and its load-dependent
physiology. Its shape in apical 4-chamber view is more triangular, in contrast to the left
ventricle more conical. In the parasternal short axis view, it is like a crescent. The cavity
of the RV has three parts: inlet, apical trabeculae, and outlet segments. The outlet
segment is not trabeculated and is separated from the inlet segment by the supraventricular crest. The subepicardial myofibrils have a circumferential orientation, and the
subendocardial myofibrils have predominantly a longitudinal orientation [9, 10]. The
interventricular septum separates the right and left ventricles and bulges into RV during
the ventricular systole. From the three leaflets of the tricuspid valve, the septal leaflet is
usually visible by echocardiography. The 2D echography has a low sensitivity for defining the RV endocardial border contour of the free wall and of the apex. The complex
morphology of the RV makes the correct echocardiographic evaluation difficult and
implies great variation in the 2D measurement results of the RV diameters and area. In a
study that included 900 patients, Tamborini G. et al. [11] demonstrated high inter- and
intraobserver variabilities in the measurements of RV fractional area change (FAC), a
parameter of RV systolic function. There are also difficulties in the echocardiographic
examination of the right atria (RA). RA has an ellipsoid shape and includes crista
terminalis, RA appendage, cavotricuspid isthmus, Eustachian valve, the orifice of the
coronary sinus, and Thebesian valve. Echographic data include RA indexed major and
minor axis length and systolic RA volume. The values are different in men and women,
and the indexed RA volume using the single-plane method of disks has lower values
than those obtained by the area-length method [12]. RA becomes dilated, and a process
of RA remodeling occurs in longstanding PH. The RA pressure (RAP) increases, and its
evaluation according to the diameter and inspiratory changes of the inferior vena cava
(IVC) is an important parameter for the evaluation of RV systolic pressure in the
absence of significant RV outflow tract obstruction. The RAP estimated non-invasively
is the main source of errors in the assessment of both sPAP and mPAP. sPAP is
calculated using the maximal velocity of tricuspid regurgitation flow (Figure 1)and
mPAP by formulas that use pulmonary regurgitation flow velocity at the beginning of
the diastole or pulmonary velocity acceleration time. Both can underestimate the PH in
case of RV failure. RV failure can impede the left ventricle (LV) function by many
mechanisms. So assessing the RV and LV morphology and function is essential for the
correct diagnosis and prognostic of PH. The echocardiographic evaluation of the right
heart can be improved through other methods, such as agitated saline study, echocardiographic contrast agents, speckle tracking, and 3D echocardiography [13]. 2D RV
longitudinal strain of the free wall (RV-FWS) and 2D RV global longitudinal strain (RVGLS), which includes in the analysis of the interventricular septum, can demonstrate
subclinical impairment of the longitudinal contraction in patients with PH. The method
is less angle and load-dependent and less influenced by the complex geometry of RV,
but it depends on image quality that can be poor because of many artifacts [14, 15]. The
analysis of segmental contractility of the RV walls by strain technique offers information about the pattern of RV remodeling in PH. The cut-off value proposed for RV-FWS
is 23% and 20% for RV-GLS. For now, there is no consensus on which method to
use, but it seems that RV-FWS is more useful. The 3D technique is more accurate than
the 2D technique in the evaluation of RV strain.
2
Соседние файлы в папке Библиотека им академика М.И. Перельмана
